Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

35.06USD
7 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$35.06
Open
$35.86
Day's High
$36.39
Day's Low
$34.12
Volume
212,503
Avg. Vol
257,578
52-wk High
$73.90
52-wk Low
$17.40

Chart for

About

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct... (more)

Overall

Beta: --
Market Cap(Mil.): $1,884.90
Shares Outstanding(Mil.): 51.90
Dividend: --
Yield (%): --

Financials

  CRSP.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -2.35 -- --
ROI: -29.32 0.60 13.80
ROE: -37.21 -2.18 15.29

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

Jul 16 2018

UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study

LONDON, July 16 Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

Jul 16 2018

Earnings vs. Estimates